{"id":2526,"date":"2017-01-04T00:00:00","date_gmt":"2017-01-03T23:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/"},"modified":"2019-01-13T16:39:23","modified_gmt":"2019-01-13T15:39:23","slug":"04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/","title":{"rendered":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion"},"content":{"rendered":"<p><strong><br \/><\/strong><\/p>\n<p><strong><span>NOXXON continues transition to clincal oncology company<\/span><\/strong><\/p>\n<p><strong>Berlin, Germany, January 04, 2017<\/strong> &#8211; NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion.<\/p>\n<p>NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer\u00ae technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.<\/p>\n<p>\u201cThis agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.\u201d commented Aram Mangasarian, CEO of NOXXON.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2526\" data-postid=\"2526\" class=\"themify_builder_content themify_builder_content-2526 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->\n","protected":false},"excerpt":{"rendered":"<p>NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-03T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:39:23+00:00\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion\",\"datePublished\":\"2017-01-03T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\"},\"wordCount\":174,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\",\"url\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\",\"name\":\"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-01-03T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO","og_url":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-01-03T23:00:00+00:00","article_modified_time":"2019-01-13T15:39:23+00:00","author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion","datePublished":"2017-01-03T23:00:00+00:00","dateModified":"2019-01-13T15:39:23+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/"},"wordCount":174,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/","url":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/","name":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-01-03T23:00:00+00:00","dateModified":"2019-01-13T15:39:23+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/04-01-17-noxxon-pharma-licenses-and-assigns-preclinical-spiegelmer-programs-to-aptarion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2526"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2526"}],"version-history":[{"count":1,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2526\/revisions"}],"predecessor-version":[{"id":2651,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2526\/revisions\/2651"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}